Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
13 06 2019
13 06 2019
Historique:
pubmed:
14
6
2019
medline:
8
2
2020
entrez:
14
6
2019
Statut:
epublish
Résumé
Cystic fibrosis (CF) a life-limiting inherited disease affecting a number of organs, but classically associated with chronic lung infection and progressive loss of lung function. Chronic infection by Burkholderia cepacia complex (BCC) is associated with increased morbidity and mortality and therefore represents a significant challenge to clinicians treating people with CF. This review examines the current evidence for long-term antibiotic therapy in people with CF and chronic BCC infection. The objective of this review is to assess the effects of long-term oral and inhaled antibiotic therapy targeted against chronic BCC lung infections in people with CF. The primary objective is to assess the efficacy of treatments in terms of improvements in lung function and reductions in exacerbation rate. Secondary objectives include quantifying adverse events, mortality and changes in quality of life associated with treatment. We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched online trial registries and the reference lists of relevant articles and reviews.Date of last search: 29 May 2019. Randomised controlled trials (RCTs) of long-term antibiotic therapy in people with CF and chronic BCC infection. Two authors independently extracted data, assessed risk of bias and assessed the quality of the evidence using GRADE. We included one RCT (100 participants) which lasted 52 weeks comparing continuous inhaled aztreonam lysine (AZLI) and placebo in a double-blind RCT for 24 weeks, followed by a 24-week open-label extension and a four-week follow-up period. The average participant age was 26.3 years, 61% were male and average lung function was 56.5% predicted.Treatment with AZLI for 24 weeks was not associated with improvement in forced expiratory volume in one second (FEV We found insufficient evidence from the literature to determine an effective strategy for antibiotic therapy for treating chronic BCC infection.
Sections du résumé
BACKGROUND
Cystic fibrosis (CF) a life-limiting inherited disease affecting a number of organs, but classically associated with chronic lung infection and progressive loss of lung function. Chronic infection by Burkholderia cepacia complex (BCC) is associated with increased morbidity and mortality and therefore represents a significant challenge to clinicians treating people with CF. This review examines the current evidence for long-term antibiotic therapy in people with CF and chronic BCC infection.
OBJECTIVES
The objective of this review is to assess the effects of long-term oral and inhaled antibiotic therapy targeted against chronic BCC lung infections in people with CF. The primary objective is to assess the efficacy of treatments in terms of improvements in lung function and reductions in exacerbation rate. Secondary objectives include quantifying adverse events, mortality and changes in quality of life associated with treatment.
SEARCH METHODS
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched online trial registries and the reference lists of relevant articles and reviews.Date of last search: 29 May 2019.
SELECTION CRITERIA
Randomised controlled trials (RCTs) of long-term antibiotic therapy in people with CF and chronic BCC infection.
DATA COLLECTION AND ANALYSIS
Two authors independently extracted data, assessed risk of bias and assessed the quality of the evidence using GRADE.
MAIN RESULTS
We included one RCT (100 participants) which lasted 52 weeks comparing continuous inhaled aztreonam lysine (AZLI) and placebo in a double-blind RCT for 24 weeks, followed by a 24-week open-label extension and a four-week follow-up period. The average participant age was 26.3 years, 61% were male and average lung function was 56.5% predicted.Treatment with AZLI for 24 weeks was not associated with improvement in forced expiratory volume in one second (FEV
AUTHORS' CONCLUSIONS
We found insufficient evidence from the literature to determine an effective strategy for antibiotic therapy for treating chronic BCC infection.
Identifiants
pubmed: 31194880
doi: 10.1002/14651858.CD013079.pub2
pmc: PMC6564086
doi:
Substances chimiques
Anti-Bacterial Agents
0
Aztreonam
G2B4VE5GH8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD013079Commentaires et corrections
Type : UpdateIn
Références
Am J Ther. 1995 Feb;2(2):81-87
pubmed: 11847533
Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8
pubmed: 18658109
Syst Appl Microbiol. 2011 Apr;34(2):87-95
pubmed: 21257278
Cochrane Database Syst Rev. 2019 Apr 18;4:CD009876
pubmed: 30997925
Am J Respir Crit Care Med. 2003 Mar 15;167(6):841-9
pubmed: 12480612
Eur Respir J. 2015 Jul;46(1):133-41
pubmed: 25792639
Thorax. 2004 Nov;59(11):948-51
pubmed: 15516469
Cochrane Database Syst Rev. 2019 Jun 13;6:CD013079
pubmed: 31194880
Int J Epidemiol. 2002 Feb;31(1):140-9
pubmed: 11914310
Pediatr Pulmonol. 2008 Jan;43(1):47-58
pubmed: 18041081
J Infect Dis. 1999 May;179(5):1190-6
pubmed: 10191222
J Cyst Fibros. 2008 Sep;7(5):450-3
pubmed: 18442953
Ann Am Thorac Soc. 2015 Jan;12(1):70-8
pubmed: 25474359
Aust Paediatr J. 1984 Mar;20(1):43-5
pubmed: 6466215
Thorax. 1998 May;53(5):432-6
pubmed: 9708241
J Cyst Fibros. 2014 May;13(3):241-2
pubmed: 24485846
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Thorax. 1999 Aug;54 Suppl 2:S58-62
pubmed: 10451695
Clin Infect Dis. 2001 Nov 1;33(9):1469-75
pubmed: 11588691
J Aerosol Med. 2002 Spring;15(1):51-7
pubmed: 12006145
Paediatr Respir Rev. 2012 Dec;13(4):228-9
pubmed: 23069121
J Cyst Fibros. 2003 Mar;2(1):29-34
pubmed: 15463843
J Pediatr. 1997 Dec;131(6):809-14
pubmed: 9427882
Clin Microbiol Infect. 2010 Jul;16(7):821-30
pubmed: 20880411
N Engl J Med. 1999 Jan 7;340(1):23-30
pubmed: 9878641
Am J Respir Crit Care Med. 2001 Dec 1;164(11):2102-6
pubmed: 11739142
Chron Respir Dis. 2005;2(2):85-98
pubmed: 16279156
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD001021
pubmed: 21412868
J Cyst Fibros. 2014 May;13(3):296-305
pubmed: 24176390
J Cyst Fibros. 2017 Jul;16(4):492-495
pubmed: 28262569
Clin Microbiol Rev. 2010 Apr;23(2):299-323
pubmed: 20375354
J Med Microbiol. 2002 Jul;51(7):533-538
pubmed: 12132768
Cochrane Database Syst Rev. 2016 Jan 20;(1):CD009529
pubmed: 26789750